SCHEMBL2076023

SCHEMBL2076023

Cn1nc(-c2cnccn2)c(CSc2ccccc2C(=O)O)c1Cl

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
TDP1 Q9NUW8 4/20 0.45
NPSR1 Q6W5P4 1/20 0.45
MAPT P10636 3/20 0.42
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.41
PTPRG P23470 1/20 0.40
RAB9A P51151 7/20 0.39
NPC1 O15118 5/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
USP2 O75604 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MPO P05164 1/20 0.38
POLB P06746 2/20 0.37
TP53 P04637 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
PIEZO1 Q92508 1/20 0.36
CYP1A2 P05177 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2078253 0.83 ALDH1A1 (0.72) ALDH1A1TDP1NPSR1MAPTLMNA
SCHEMBL2076018 0.81 KDR (0.47) ALDH1A1RAB9ANPC1SMN1; SMN2HSD17B10
SCHEMBL2078924 0.76 ALDH1A1 (0.70) ALDH1A1TDP1NPSR1MAPTLMNA
SCHEMBL2077506 0.72 KDR (0.48) ALDH1A1RAB9ANPC1SMN1; SMN2HSD17B10
SCHEMBL2078363 0.72 CYP2C9 (0.48) ALDH1A1MAPTLMNAGAARAB9A
SCHEMBL2075725 0.69 KDR (0.47) ALDH1A1TDP1NPSR1RAB9ANPC1
SCHEMBL2078805 0.69 CYP2C9 (0.48) ALDH1A1TDP1NPSR1MAPTLMNA
SCHEMBL2078831 0.68 NPC1 (0.45) ALDH1A1TDP1NPSR1MAPTGAA
SCHEMBL2077519 0.68 KDR (0.48) ALDH1A1TDP1NPSR1RAB9ANPC1
SCHEMBL2077184 0.68 ALDH1A1 (0.52) ALDH1A1TDP1NPSR1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110059964-A1 PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS SANOFI-AVENTIS (FR) 2011-03-10 US disclosed
US-7659298-B2 2-(3-Phenyl-5-chloro-1-methyl-1H-pyrazol-4-ylmethylsulphanyl)-N-quinolin-3-ylbenzamide; 2-(3-Phenyl-5-chloro-1-methyl-1H-pyrazol-4-ylmethoxy)-N-naphthalin-2-ylbenzamide; obesity, including obesity of the non-insuline-dependent diabetes patients, sleeping disorders, stroke, nausea and vomiting SANOFI-AVENTIS (FR) 2010-02-09 US disclosed
EP-1699454-B1 PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS SANOFI AVENTIS (FR) 2009-08-05 EP disclosed
US-20070021459-A1 PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS SANOFI-AVENTIS (FR) 2007-01-25 US disclosed
EP-1699454-A1 PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS Sanofi-Aventis (FR) 2006-09-13 EP disclosed
WO-2005060959-A1 PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS SANOFI-AVENTIS (FR) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021459-A1 PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPY1R ALDH1A1 2239/4885TDP1 4727/4885NPSR1 8/4885
US-20110059964-A1 PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPY1R ALDH1A1 2239/4885TDP1 4727/4885NPSR1 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.